| Title |
Oral Zinc Sulphate Supplementation for Six Months in SCA2 Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
|
|---|---|
| Published in |
Neurochemical Research, May 2011
|
| DOI | 10.1007/s11064-011-0496-0 |
| Pubmed ID | |
| Authors |
Luis Velázquez-Pérez, Jorge Rodríguez-Chanfrau, Julio Cesar García-Rodríguez, Gilberto Sánchez-Cruz, Raúl Aguilera-Rodríguez, Roberto Rodríguez-Labrada, Julio Cesar Rodríguez-Díaz, Nalia Canales-Ochoa, Dennis Almaguer Gotay, Luis E. Almaguer Mederos, José M. Laffita Mesa, Marlene Porto-Verdecia, Consuelo González Triana, Noemí Rodríguez Pupo, Idania Hidalgo Batista, Orestes D. López-Hernandez, Iverlis Díaz Polanco, Arelis Jayme Novas |
| Abstract |
Cuban patients with Spinocerebellar Ataxia type 2 (SCA2) have reduced concentrations of zinc in serum and cerebrospinal fluid (CSF). To assess the effect and safety of zinc supplementation, 36 Cuban SCA2 patients were randomly assigned to receive daily either 50 mg ZnSO(4) or placebo, together with neurorehabilitation therapy in a randomized, double-blind, placebo-controlled clinical trial during 6 months. Outcome measures included the changes of zinc levels in CSF and serum, ataxia score, oxidative stress and saccadic eye movements. At the end of the study, the Zinc-treated group showed: (i) a significant increase of the Zn levels in the CSF, (ii) mild decrease in the ataxia scale subscores for gait, posture, stance and dysdiadochocinesia (iii) reduction of lipid's oxidative damage, and (iv) reduction of saccadic latency when compared with the placebo group. The treatment was safe and well tolerated by all subjects. This study demonstrated the efficacy and safety of Zn supplementation, combined with neurorehabilitation for SCA2 patients and therefore it may encourage further studies on the clinical effect of zinc supplementation in SCA2 based in the conduction of future clinical trials with higher number of subjects. |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 2% |
| Unknown | 60 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 16% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Bachelor | 6 | 10% |
| Other | 6 | 10% |
| Student > Postgraduate | 6 | 10% |
| Other | 8 | 13% |
| Unknown | 18 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 25% |
| Agricultural and Biological Sciences | 6 | 10% |
| Neuroscience | 6 | 10% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Nursing and Health Professions | 3 | 5% |
| Other | 10 | 16% |
| Unknown | 18 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2014.
All research outputs
#18,385,510
of 22,772,779 outputs
Outputs from Neurochemical Research
#1,486
of 2,092 outputs
Outputs of similar age
#94,820
of 109,817 outputs
Outputs of similar age from Neurochemical Research
#9
of 13 outputs
Altmetric has tracked 22,772,779 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,092 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 109,817 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.